Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Assets (2022 - 2025)

Historic Assets for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $11.5 million.

  • bioAffinity Technologies' Assets rose 7622.63% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 7622.63%. This contributed to the annual value of $6.5 million for FY2024, which is 2077.33% down from last year.
  • bioAffinity Technologies' Assets amounted to $11.5 million in Q3 2025, which was up 7622.63% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Assets registered a high of $14.1 million during Q3 2022, and its lowest value of $4.8 million during Q2 2025.
  • Moreover, its 4-year median value for Assets was $8.2 million (2023), whereas its average is $8.7 million.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 3569.81% in 2024, then surged by 7622.63% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Assets stood at $12.2 million in 2022, then tumbled by 32.51% to $8.2 million in 2023, then fell by 20.77% to $6.5 million in 2024, then surged by 77.26% to $11.5 million in 2025.
  • Its Assets was $11.5 million in Q3 2025, compared to $4.8 million in Q2 2025 and $5.5 million in Q1 2025.